

Poster Program



apsa 
Australasian Pharmaceutical Science Association

APSA-ASCEPT

JOINT SCIENTIFIC MEETING 2015

Drugs to medicines: up close and personal

29 November - 2 December 2015
Hotel Grand Chancellor Hobart


ASCEPT

www.apsa-accept2015.com

Monday, 30 November

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
400	Deprescribing feasibility study in New Zealand residential care homes	Mrs Nagham Ailabouni	400	APSA - Pharmacy Practice
401	Systematic review of medication reconciliation best practice	Mrs Enas Almanasreh	401	APSA - Pharmacy Practice
402	Perspective of pharmacists about their role in religious fasts observed by diabetic patients	Mr Hadi Almansour	402	APSA - Pharmacy Practice
403	What might a community pharmacy triage service look like? A Delphi study	Dr Trudi Aspden	403	APSA - Pharmacy Practice
404	Culturally competent community pharmacy practice: Exploring the perspectives of those with disabilities	Dr Trudi Aspden	404	APSA - Pharmacy Practice
405	Professionalism of pharmacists on social network sites	Assoc Prof Parisa Aslani	405	APSA - Pharmacy Practice
406	Development and validation of an oral anticoagulant knowledge instrument	Assoc Prof Luke Bereznicki	406	APSA - Pharmacy Practice
407	Development of a score to predict hospitalisation due to adverse drug reactions in older patients	Assoc Prof Luke Bereznicki	407	APSA - Pharmacy Practice
408	Potential medicine sharing risk reduction strategies: A qualitative analysis of patients' and health professionals' views using the Behaviour Change Wheel	Mr Kebede Beyene	228	APSA - Pharmacy Practice
409	The impact of psycholeptic reduction in residential aged care facilities: Preliminary findings	Dr Ivan Bindoff	409	APSA - Pharmacy Practice
410	Purchasing over-the-counter medicines from the pharmacy: Does a consumer's health status, perceptions and what they value matter?	Dr Vincent Chan	410	APSA - Pharmacy Practice
411	Examining hospital pharmacists' goals for medication counselling within the communication accommodation theoretical framework	Ms Bernadette Chevalier	124	APSA - Pharmacy Practice
412	Can pharmacists in Australia and Switzerland improve access to chlamydia screening?	Prof Rhonda Clifford	412	APSA - Pharmacy Practice
413	Enhancing communication between consumers and community pharmacy staff for over the counter requests: A systematic review.	Prof Rhonda Clifford	413	APSA - Pharmacy Practice
414	Barriers to the treatment of gout: A community pharmacy perspective	Miss Allyce Counsell	414	APSA - Pharmacy Practice
415	Preliminary results of Vitamin D supplementation in residents of aged care facilities	Dr Colin Curtain	415	APSA - Pharmacy Practice
416	Postpartum depression screening by pharmacists in primary care: A literature review	Ms Sabine Elkhodr	416	APSA - Pharmacy Practice
417	Exploring the role of health beliefs in medication adherence in individuals with asthma	Ms Holly Foot	125	APSA - Pharmacy Practice
418	Product recommendations for teething in young children	Ms Brittany Martin	418	APSA - Pharmacy Practice
419	Indonesian hospital pharmacists' roles and responsibilities	Ms Vania Gones	419	APSA - Pharmacy Practice
420	Development of a cognitive framework for pharmaceutical care: ASE-C-POP	Mr Tony Hall	420	APSA - Pharmacy Practice
421	Antimicrobial stewardship in paediatric oncology – optimising gentamicin use in febrile neutropenia	Dr Stefanie Hennig	421	APSA - Pharmacy Practice
422	An evaluation of using fish oil among Australian patients with rheumatoid arthritis through medicine review	Dr Sam Kosari	422	APSA - Pharmacy Practice
423	General practitioner-pharmacist collaborations to improve patients' adherence to medication	Dr Sarab Mansoor	423	APSA - Pharmacy Practice
424	What do health consumers want to know about childhood vaccination?	Dr Treasure McGuire	424	APSA - Pharmacy Practice
425	Consumer perceptions of service quality in Australian community pharmacies	Mr Ardalan Mirzaei	123	APSA - Pharmacy Practice
426	Using the technology: The novel use of a smart phone app to assess the potential redistribution of dispensary tasks	Mrs Patti Napier	426	APSA - Pharmacy Practice
427	The introduction of an advance role for technicians facilitates greater patient focused activities for pharmacists	Mrs Patti Napier	427	APSA - Pharmacy Practice
428	A systematic review and meta-analysis on serum anticholinergic activity and adverse outcomes in older people	Dr Mohammed Saji Salahudeen	428	APSA - Pharmacy Practice
429	Organisational climate related to the use of psychotropic medicines in Australian Nursing Homes: The role of managers	Miss Mouna Sawan	429	APSA - Pharmacy Practice
430	Medicine Procurement in hospital pharmacies of Nepal: A qualitative study based on the Basel Statements	Miss Mina Shrestha	430	APSA - Pharmacy Practice
431	Exploring the shift in management autonomy between caregivers and children when taking asthma medication: A caregiver's perspective	Ms Pamela Srouf	431	APSA - Pharmacy Practice
432	Systematic review of the effect of vitamin D on women's mental health during the perinatal period	Mrs Arwa Sultan	432	APSA - Pharmacy Practice
433	Community pharmacist practices, attitudes, recommendations, information and education needs for herbal and nutrient complementary medicines for weight loss	Dr Meng-Wong Taing	433	APSA - Pharmacy Practice
434	Up close and personal with those experiencing homelessness: Pharmacist involvement in a multidisciplinary healthcare team	Mr Hung Tran	434	APSA - Pharmacy Practice
435	Pharmacists' perspectives in optimising statin therapy in older inpatients	Dr Danijela Gnjidic	435	APSA - Pharmacy Practice
480	HNO donor isopropylamine NONOate offers haemodynamic advantages over the NO donor diethylamine NONOate in the diabetic rat myocardium ex vivo	Mr Jarryd Anthonisz	136	ASCEPT - Cardiovascular
481	Adenosine A1 receptor biased agonism in ventricular cardiomyocytes	Miss Jo-Anne Baltos	481	ASCEPT - Cardiovascular
482	Loss of Alzheimer's-associated tau (MAPT) impairs cardiovascular function	Mr Ashenafi Haileyesus Betrie	137	ASCEPT - Cardiovascular

Monday, 30 November (cont'd)

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
483	Cardiac-specific insulin-like growth factor-1 receptor over-expression attenuates diabetes-induced upregulation of hexosamine biosynthesis pathway and oxidative stress in diabetic mouse myocardium	Dr Miles De Blasio	483	ASCEPT - Cardiovascular
484	Decreased vascular hydrogen sulfide production is associated with vascular oxidative stress in rats fed a high-fat western diet	Dr Joanne Hart	484	ASCEPT - Cardiovascular
485	Initial clinical experience with pharmacological conditioning of brain dead donor hearts with glyceryl trinitrate and erythropoietin	Dr Mark Hicks	485	ASCEPT - Cardiovascular
486	Hyperglycaemia and systemic inflammation precede the cardiac complications of type 1 diabetes in mice	Mr Nguyen Huynh	486	ASCEPT - Cardiovascular
487	MDM2 E3 ligase-mediated ubiquitination of HDAC1 in vascular calcification	Prof Hyun Kook	487	ASCEPT - Cardiovascular
488	Roles of orphan nuclear receptors, estrogen-related receptor gamma and small heterodimer partner, in cardiac hypertrophy	Prof Hyun Kook	488	ASCEPT - Cardiovascular
489	Pharmacological inhibition of Insulin Regulated Aminopeptidase (IRAP) completely reverses age-mediated cardiac fibrosis	Miss Huey Wen Lee	217	ASCEPT - Cardiovascular
490	The effects of Th2 cytokines to modulate macrophage phenotype and reactive oxygen species generation	Ms Tara McConaghy	139	ASCEPT - Cardiovascular
491	Ligand-directed signalling and beta3-adrenoceptors in the rat cremaster muscle artery	Dr Tim Murphy	491	ASCEPT - Cardiovascular
492	Phosphoinositide 3-kinase [p110alpha] (PI3K) gene therapy attenuates type 1 diabetic cardiomyopathy in mice	Mr Darnel Prakoso	138	ASCEPT - Cardiovascular
493	Deficiency of endogenous annexin-A1 exaggerates cardiomyopathy in a mouse model of type 1 diabetes	Ms Sarah Rosli	141	ASCEPT - Cardiovascular
494	Australian native stingless bee (<i>Tetragonula carbonaria</i>) cerumen modulates dermal fibroblast proliferation, migration and differentiation in vitro	Dr Fraser Russell	494	ASCEPT - Cardiovascular
495	Modulation of the β_2 -adrenergic receptor pathway during the onset of myocardial sustained ligand-activated preconditioning	Miss Louise See Hoe	495	ASCEPT - Cardiovascular
496	Post-Ischaemic Mitochondrial Bioenergetics in a Murine Model of Type II Diabetes following Inhibition of Mitochondrial Fission	Miss Louise See Hoe	496	ASCEPT - Cardiovascular
497	Comparison of the anti-fibrotic effects of Serelaxin with an ARB and an AT2 receptor agonist in high salt-induced kidney disease	Mr Matthew Shen	497	ASCEPT - Cardiovascular
498	Inhibition of vanilloid-induced platelet aggregation is independent of thromboxane biosynthesis and granule release	Dr Safa Almaghrabi	498	ASCEPT - Cardiovascular
499	NOX2 Oxidase Promotes Prostate Tumour Development	Mr Ian Harrison	134	ASCEPT - Cardiovascular
511	Medication errors in patients undergoing elective surgery	Ms Tracey Borrie	511	ASCEPT - Clinical Pharmacology
512	Medicine information exchange networks among health care professionals and prescribing in geriatric medicine wards	Mr Bosco Chan	160	ASCEPT - Clinical Pharmacology
513	Investigating the selectivity of ginsenoside positive modulators on P2X7	Mrs Kshitija Dhuna	513	ASCEPT - Clinical Pharmacology
514	Pilot study showing "AderenceCheck" does not improve the management of medicines in the older-aged living in a rental retirement village	Dr Sheila Doggrell	514	ASCEPT - Clinical Pharmacology
515	Systemic inflammation predicts drug pharmacokinetics and clinical outcomes in advanced non-small cell lung cancer patients receiving paclitaxel and carboplatin chemotherapy	Mr Benjamin Harris	233	ASCEPT - Clinical Pharmacology
516	Gentamicin pharmacokinetics and monitoring in paediatric febrile neutropenic patients	Dr Stefanie Hennig	516	ASCEPT - Clinical Pharmacology
517	Digoxin withdrawal in stable heart failure with reduced ejection fraction in sinus rhythm - a randomised controlled trial	Dr Ingrid Hopper	219	ASCEPT - Clinical Pharmacology
518	A LCMSMS method for amisulpride in human plasma and breast milk, applied to measuring transfer to a fully breast-fed neonate	Prof David Joyce	518	ASCEPT - Clinical Pharmacology
519	A simple and precise assay for the determination of febuxostat in human plasma	Mr Bishoy Kamel	519	ASCEPT - Clinical Pharmacology
520	Febuxostat: An analysis of its dose-response relationship with serum urate	Mr Diluk Kannangara	238	ASCEPT - Clinical Pharmacology
521	The pattern of anticholinergic medication prescribing in elderly hospital inpatients	Dr Amanda Khoo	521	ASCEPT - Clinical Pharmacology
522	Metformin and weight loss: An exposure-response relationship	Mr Shaun Kumar	239	ASCEPT - Clinical Pharmacology
523	Population pharmacokinetic modelling as tool to personalise gentamicin therapy	Miss Carolina Llanos-Paez	523	ASCEPT - Clinical Pharmacology
524	Therapeutic drug monitoring trials for gastrointestinal stromal tumours treated with sunitinib cannot be expected to detect clinical outcome improvement	Prof Anthony Smith	524	ASCEPT - Clinical Pharmacology
525	Complex patients, polypharmacy and guidelines	Ms Annabelle McGowan	525	ASCEPT - Clinical Pharmacology
526	LC-MSMS method to describe the pharmacokinetics of aerosolised lincomycin and tobramycin at the site of infection	Ms Suzanne Parker	526	ASCEPT - Clinical Pharmacology
527	A suite of LC-MSMS assays to investigate pharmacokinetics of vancomycin in renal replacement therapy	Ms Suzanne Parker	527	ASCEPT - Clinical Pharmacology
528	Quantitative bioanalytical validation of fosfomycin using innovative techniques of microsampling	Ms Suzanne Parker	528	ASCEPT - Clinical Pharmacology

Monday, 30 November (cont'd)

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
529	A validated UHPLC-MS/MS method for measurement of riluzole in plasma and cardiac tissue samples	Ms Suzanne Parker	529	ASCEPT - Clinical Pharmacology
530	Metformin in pregnant women with type 2 diabetes mellitus: Update on safety and efficacy	Dr Thomas Polasek	530	ASCEPT - Clinical Pharmacology
531	Safety and pharmacokinetics of metformin in chronic liver disease	Miss Felicity Smith	531	ASCEPT - Clinical Pharmacology
532	The safe use of Metformin in patients with end stage kidney disease on haemodialysis	Miss Felicity Smith	532	ASCEPT - Clinical Pharmacology
533	The role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1) inhibition in experimental angiogenesis	Ms Negara Tajbakhsh	533	ASCEPT - Clinical Pharmacology
534	Evaluating a natural remedy for Cholelithiasis (gallstones)	Prof Michael Whitehouse	534	ASCEPT - Clinical Pharmacology
535	Determination of total and free concentrations of cefalexin, cefazolin, flucloxacillin and probenecid in human plasma by liquid chromatography/tandem mass spectrometry	Dr Mei Zhang	535	ASCEPT - Clinical Pharmacology
551	Signal transduction pathways activated by insulin-like Peptide 5 at relaxin family Peptide Receptor 4	Mr Sheng Yu Ang	551	ASCEPT - Drug Discovery
552	Development of an MDA-MB-231 breast cancer cell line stably expressing a GCaMP6 genetically encoded calcium indicator	Mr John Bassett	552	ASCEPT - Drug Discovery
553	Assessment of the effects of genistein and resveratrol in an MDA-MB-231 breast cancer cell line expressing a genetically-targeted calcium sensor	Miss Alice Hui Li Bong	553	ASCEPT - Drug Discovery
554	Morphological changes associated with cell death by Transient Receptor Potential Cation Channel V4 (TRPV4) activation in MDA-MB-468 breast cancer cells	Ms Silke Chalmers	554	ASCEPT - Drug Discovery
555	Regulation of copper transporters by platinum-based anticancer drug oxaliplatin and copper chelators in colorectal cancer cells	Mr Haigang Cui	555	ASCEPT - Drug Discovery
556	ERK phosphorylation induced by adrenergic agonists in CHO cells expressing low levels of α 1A-adrenoceptors: differential effects of oxymetazoline and noradrenaline	Dr Edilson Dantas Da Silva Junior	556	ASCEPT - Drug Discovery
557	Insights into allosteric structure-function relationships at the M5 muscarinic acetylcholine receptor	Dr Patrick Gentry	557	ASCEPT - Drug Discovery
558	Calcium signalling and the acquisition of trastuzumab resistance in HER2-positive breast cancer cells	Dr Elke Kaemmerer	558	ASCEPT - Drug Discovery
559	Inhibition of incretin receptors for the prevention of hyperinsulinaemia in horses	Mr Murad Kheder	559	ASCEPT - Drug Discovery
560	Aryl group modification in novel anti-cancer agents based on ω -3-17,18-epoxyeicosapentaenoic acid	Mrs Nooshin Koolaji	560	ASCEPT - Drug Discovery
561	Drug discovery twist – Are aminooxazolopyridine compounds carcinogenic?	Mr Hsien Hooi Lee	561	ASCEPT - Drug Discovery
562	Assessment of the effects of NH125 on HCC1569 human breast cancer cells	Ms Sandrine Leogite	562	ASCEPT - Drug Discovery
563	Transient Receptor Potential Cation Channel V4 (TRPV4) expression in breast cancer subtypes and potential expression regulators in breast cancer cells	Ms Huai Lim	563	ASCEPT - Drug Discovery
564	Probing the pharmacology of the α 1A-adrenoceptor with fluorescent prazosin	Miss Linzi Lim	146	ASCEPT - Drug Discovery
565	Glucose lowering effect of Teucrium polium; mechanistic insight	Mr Adnan Mannan	565	ASCEPT - Drug Discovery
566	Pharm-Ecology: The mutualistic interactions of two disciplines brings research opportunities	Prof Stuart McLean	566	ASCEPT - Drug Discovery
567	Endogenous allosteric modulators of G protein-coupled receptors - unappreciated mediators of health and disease?	Ms Ee Von Moo	567	ASCEPT - Drug Discovery
568	Role of cyclic AMP in BRL37344 and isoprenaline mediated glucose uptake by β 2-adrenoceptors	Miss Saori Mukaida	568	ASCEPT - Drug Discovery
569	New synthetic targets for the inhibition of dimethylarginine dimethylaminohydrolase (DDAH): A pre-synthetic computational study	Mr Rhys Murphy	569	ASCEPT - Drug Discovery
570	Novel naphthoquinones against mitochondrial dysfunction-induced seizures	Ms Monila Nadikudi	331	ASCEPT - Drug Discovery
571	Ethnicity information included in US Prescribing Information on initial registration: 2006 to 2015	Dr Romina A Nand	571	ASCEPT - Drug Discovery
572	Allosteric modulators of metabotropic glutamate receptor subtype 5 show biased agonism and modulation	Miss Kathy Sengmany	572	ASCEPT - Drug Discovery
573	Compounds Australia – bringing biologists and chemists together	Ms Moana Simpson	573	ASCEPT - Drug Discovery
574	Assessment of the potential remodelling of calcium signalling in human breast cancer-associated fibroblasts	Ms Teneale Stewart	220	ASCEPT - Drug Discovery
575	Design and synthesis of arginine analogues incorporating carboxylate bioisosteres as DDAH-1 inhibitors	Ms Sara Tommasi	575	ASCEPT - Drug Discovery
576	Consequences of Transient Receptor Potential Cation Channel V4 (TRPV4) activation in MDA-MB-468 breast cancer cells	Miss Kunsala T.D.S Yapa	576	ASCEPT - Drug Discovery
577	Small molecule inhibitors on LOXL2 for fibrosis	Dr Tin Yow	577	ASCEPT - Drug Discovery
578	A fat chance for improving brain cancer treatment?	Mr Raymond Yung	578	ASCEPT - Drug Discovery
579	Preclinical pharmacological evaluation of CDKI-73 for treatment of acute myeloid leukaemia	Ms Longjin Zhong	332	ASCEPT - Drug Discovery

Tuesday, 1 December

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
451	Comparison of sample preparation methods used for vitamin D LC-MS assay	Miss Nur Sofiah Abu Kassim	451	APSA - Pharmaceutical Science
452	Glucosamine in Osteoarthritis- Why do trials differ?	Mrs Chhavi Asthana	452	APSA - Pharmaceutical Science
453	Investigation of amyloid plaques and enoxaparin brain penetration using Raman and infrared spectroscopy	Dr Glenn Jacobson	453	APSA - Pharmaceutical Science
454	Exploring buccal mucosal and pulmonary delivery of the scorpion peptide HsTX1 [R14A] for the treatment of autoimmune diseases	Dr Liang Jin	454	APSA - Pharmaceutical Science
455	Selection of pharmaceutical vehicles for development of liquid dosage form of Omeprazole	Ms Krishna Kathawala	455	APSA - Pharmaceutical Science
456	Surface characterization and morphological analysis of gliclizide microcapsules incorporating a tertiary bile acid and potential application in diabetes treatment	Mrs Sangeetha Mathavan	456	APSA - Pharmaceutical Science
457	Investigation of the antibacterial properties of the bracket fungus Ganoderma lucidum	Mrs Giuseppina Montalbano	457	APSA - Pharmaceutical Science
458	Enantiomeric separation and quantitation of Warfarin and metabolites in an overdose patient by LC-MS/MS	Dr Ahmed Mostafa	458	APSA - Pharmaceutical Science
459	Development of Ritonavir Solid Lipid Nanoparticles	Dr Usha Y Nayak	459	APSA - Pharmaceutical Science
460	Cafeteria diet induced insulin resistance in wistar rats and its prevention by quercetin	Dr Yogendra Nayak	460	APSA - Pharmaceutical Science
461	The involvement of fatty acid-binding protein 5 in the blood-brain barrier transport of docosahexaenoic acid and cognitive function	Mr Yijun Pan	333	APSA - Pharmaceutical Science
462	Stability of amorphous indomethacin suspensions in in vitro media	Dr Dorothy Saville	462	APSA - Pharmaceutical Science
463	In vitro evaluation of nicotine release from nicotine gum, Swedish snus and Pituri	Ms Melissa Siah	463	APSA - Pharmaceutical Science
464	Development of an assay for quantification of inulin in tissue samples	Ms Lixin Wang	464	APSA - Pharmaceutical Science
465	Detecting drug in saliva – a tool to determine medication compliance	Dr Kwang Choon Yee	465	APSA - Pharmaceutical Science
466	Crushing tablets: Comparison of tablet crushing devices	Ms MinYew Thong	466	APSA - Pharmaceutical Science
467	Impact of an evidence-based program on pharmacy students' communication confidence and education practices	Miss Elizabeth Azzi	467	APSA - Pharmacy Education
468	Teaching approaches in Health courses: A reflective study for curriculum redesign	Miss Elia Barajas Alonso	468	APSA - Pharmacy Education
469	Assessment of prescribing competence: Perceptions of students and teaching staff	Mrs Lynda Cardiff	469	APSA - Pharmacy Education
470	The development of mental health vignettes to assess the mental health first aid skills of final year BPharm students	Ms Sarira El-Den	470	APSA - Pharmacy Education
471	Evaluating the effectiveness of a patient safety educational intervention for intern pharmacists	Prof Andrew McLachlan	471	APSA - Pharmacy Education
472	Pharmacy and the Nasal Symptoms (PHANS)	Ms Rachel Tan	472	APSA - Pharmacy Education
473	Evaluation of second year oral assessment in pharmacy at Charles Darwin University	Dr Yean Yeow Tan	473	APSA - Pharmacy Education
474	Evaluation of oral assessment in pharmacy education at Charles Darwin University	Dr Yean Yeow Tan	474	APSA - Pharmacy Education
475	Do we have the right formula? Chemistry retention in pharmacy students	Dr Yasmin Antwertinger	475	APSA - Pharmacy Education
476	Teaching cancer therapeutics in a Postgraduate Masters Program in Pharmaceutical Medicine	Dr Orin Chisholm	476	ASCEPT - Education
477	Creating effective multimedia learning resources for the teaching of pharmacology	Ms Chau Khuong	341	ASCEPT - Education
478	What constitutes an appropriate dose of thiamine: A quality use of thiamine study at Footscray Hospital	Assoc Prof Michael McDonough	478	ASCEPT - Education
479	Flipping the classroom in pharmacology for first year graduate entry MBBS students	Assoc Prof Shane Bullock	479	ASCEPT - Education
500	Exemestane and its active metabolite 17-hydroexemestane up-regulate UDP-glucuronosyltransferase (UGT) 2B17 in breast cancer cells	Miss Apichaya Chanawong	329	ASCEPT - Drug Disposition and Response
501	Reversing the effect of cancer-related inflammation on hepatic drug-metabolising enzymes and transporters	Dr Kellie Charles	501	ASCEPT - Drug Disposition and Response
502	Drug and chemical glucosidation by untransfected Supersomes TM (u-SUP) and microsomes from <i>Spodoptera frugiperda</i> 9 (Sf9) cells	Ms Nuy Chau	328	ASCEPT - Drug Disposition and Response
503	The interactions of P-glycoprotein with antimalarial drugs, including substrate affinity and inhibition.	Dr Andrew Crowe	503	ASCEPT - Drug Disposition and Response
504	Thiopurine and Allopurinol: Together at last, in sickness and in pregnancy	Dr John Duley	504	ASCEPT - Drug Disposition and Response
505	Human Oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins	Miss Xiaoxi Lu	505	ASCEPT - Drug Disposition and Response
506	The inhibition of human UDP-glucuronosyltransferase 2B10 (UGT2B10) by antidepressant and antipsychotic drugs: Implications for drug-drug interactions	Mr Attarat Pattanawongsa	506	ASCEPT - Drug Disposition and Response
507	Pharmacokinetics of transfer of azithromycin into the breast milk of African mothers	Dr Sam Salman	507	ASCEPT - Drug Disposition and Response
508	Assessing the contribution of CYP3A4 to total cytochrome P450 mediated kinase inhibitor metabolism	Ms Madelé Van Dyk	508	ASCEPT - Drug Disposition and Response
509	A physiologically based kinetic model for elucidating the in vivo fate of mesenchymal stem cells	Dr Haolu Wang	327	ASCEPT - Drug Disposition and Response

Tuesday, 1 December (cont'd)

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
510	Regulation of UDP-glucuronosyltransferase 2B7 by microRNAs in liver cancer cell lines	Ms Dhilushi Wijayakumara	510	ASCEPT - Drug Disposition and Response
536	Diagnosis and management of early COPD in Australia: Views from the coal face	Assoc Prof Luke Bereznicki	536	ASCEPT - Inflammation/respiratory
537	Understanding the discrepancy between perceived and actual asthma control in Australia	Assoc Prof Luke Bereznicki	537	ASCEPT - Inflammation/respiratory
538	Dynorphin 1-17 and its biotransformation fragments modulate lipopolysaccharide (LPS)-induced release of interleukin-1beta and tumor necrosis factor-alpha in differentiated THP-1 cells	Mrs Siti Sarah F Rahiman	538	ASCEPT - Inflammation/respiratory
539	Differential expression of TRPV1 on circulating PBMC sub-populations assessed by confocal microscopy	Prof Dom Geraghty	539	ASCEPT - Inflammation/respiratory
540	Exploring the role of Annexin A1 in airway smooth muscle contraction and inflammation	Miss Alexandra Hall	540	ASCEPT - Inflammation/respiratory
541	Predictive factors of probability of having Aspergillus fumigatus positive culture at five years of age of children with cystic fibrosis	Mrs Sabariah Noor Harun	541	ASCEPT - Inflammation/respiratory
542	Assessing changes in airway and vascular remodelling and contraction in a mouse model of bronchopulmonary dysplasia	Mr Maurice Kroon	170	ASCEPT - Inflammation/respiratory
543	Serelaxin is an epithelial-dependent bronchodilator in rat precision cut lung slices and trachea	Miss Maggie Lam	171	ASCEPT - Inflammation/respiratory
544	Inhaled colistin is more efficacious than parenteral administration against multidrug-resistant Pseudomonas aeruginosa in a mouse lung infection model	Mr Yu-Wei Lin	544	ASCEPT - Inflammation/respiratory
545	Inhibition of NOX2 oxidase via a novel endosome specific inhibitor reduces influenza A virus (IAV)- induced lung inflammation	Mr Raymond Luong	169	ASCEPT - Inflammation/respiratory
546	The transcriptional repressor ZBTB16 is induced by glucocorticoids in human bronchial epithelial cells	Miss Danica Radojicic	546	ASCEPT - Inflammation/respiratory
547	Poly I:C and Lipopolysaccharides (LPS) impair glucocorticoid sensitivity in human bronchial epithelial cells	Ms Asmaa Radwan	547	ASCEPT - Inflammation/respiratory
548	Programming mitochondrial responses with CUTGAPS, the ancient, intermediate language of innate immunity	Mr Tim Shaw	548	ASCEPT - Inflammation/respiratory
549	NOX2 oxidase expressed in endosomes exacerbates viral pathogenicity	Miss Eunice To	166	ASCEPT - Inflammation/respiratory
550	A traditional anti-inflammatory from Tasmania: Mutton bird oil	Dr Michael Whitehouse	550	ASCEPT - Inflammation/respiratory
580	Rilmenidine increases mTOR-independent autophagy enhancing disease progression in a mouse model of Motoneuron Disease	Prof Philip M Beart	580	ASCEPT - Neuro- and Behavioural Pharmacology
581	The inhibitory effects of anti-oxidant polyphenols on beta amyloid fibrillisation and neurotoxicity in PC12 cells	Mr Chen Gao	581	ASCEPT - Neuro- and Behavioural Pharmacology
582	Receptor dwell time determines bias towards internalisation of the μ opioid receptor	Mr Alexander Gillis	322	ASCEPT - Neuro- and Behavioural Pharmacology
583	Does chronic morphine treatment alter endogenous opioid function in the amygdala?	Miss Gabrielle Gregoriou	321	ASCEPT - Neuro- and Behavioural Pharmacology
584	Stroke-related cachexia and muscle wasting: Role of the neuroendocrine hormone ghrelin	Dr Alyson Miller	584	ASCEPT - Neuro- and Behavioural Pharmacology
586	Establishment of a rat model of mechanical low back pain	Mr Thomas Park	586	ASCEPT - Neuro- and Behavioural Pharmacology
587	Mapping morphine-induced analgesic tolerance	Mr Alok Kumar Paul	587	ASCEPT - Neuro- and Behavioural Pharmacology
588	Identification of novel splice variants of GABA transporters in the central nervous system	Miss Cherubina Ratnam	588	ASCEPT - Neuro- and Behavioural Pharmacology
589	Morphine displays a distinct behaviour of antidepressant activity in the Learned Helplessness model compared to that of imipramine	Miss Xin Yin	589	ASCEPT - Neuro- and Behavioural Pharmacology
590	Medications and memory: The two big "M"s; A clinic population profiling exercise	Dr Bandana Saini Ms Zoya Aiyub	590	ASCEPT - Pharmacoepidemiology
591	Non-medical prescription and self-medication practices preceding to remedy in district Multan, Pakistan	Mr Muhammad Majid Aziz	591	ASCEPT - Pharmacoepidemiology
592	New Zealand community pharmacists' views on pharmacovigilance for natural health products	Assoc Prof Jo Barnes	592	ASCEPT - Pharmacoepidemiology
593	Antiretroviral adherence and treatment outcomes among adult Ethiopian patients	Assoc Prof Luke Bereznicki	593	ASCEPT - Pharmacoepidemiology
594	Patterns in use and costs of disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs (bDMARDs) in Australia	Miss Ellen Donges	131	ASCEPT - Pharmacoepidemiology
595	Histologically confirmed myositis and statin exposure, a case-control study	Dr Genevieve Gabb	595	ASCEPT - Pharmacoepidemiology

Tuesday, 1 December (cont'd)

9:30am - 10:25am and 12:30pm - 1:25pm

Posterboard number	Presentation title	Presenter	Paper reference	Theme
596	Evolving Australian utilisation patterns of immunosuppressants after transplantation, including comparison to Northern European countries	Mr Kyle Gardiner	596	ASCEPT - Pharmacoepidemiology
597	Lifestyle factors among statin users and non-users: Do statin users adhere to a healthy lifestyle?	Dr Jenni Ilomäki	597	ASCEPT - Pharmacoepidemiology
598	Optimising or minimising client health outcomes: Intended responses by Cambodian pharmacies to clients with prolonged cough and TB-related symptoms	Dr Jenni Ilomäki	598	ASCEPT - Pharmacoepidemiology
599	Demographic, clinical and lifestyle factors associated with high intensity statin therapy in Australia	Dr Jenni Ilomäki	599	ASCEPT - Pharmacoepidemiology
600	Why is polypharmacy increasing in aged care facilities? The views of Australian healthcare professionals	Ms Natali Jokanovic	600	ASCEPT - Pharmacoepidemiology
601	The association between polypharmacy and medication regimen complexity with quality of life in residents of aged care facilities	Ms Samanta Lalic	601	ASCEPT - Pharmacoepidemiology
602	Statin discontinuation in older people with dementia: A pharmacoepidemiological study	Ms Sujita Narayan	130	ASCEPT - Pharmacoepidemiology
603	Glucose monitoring in new users of second generation antipsychotics in older people: A population-based study	Mr Henry Ndukwe	603	ASCEPT - Pharmacoepidemiology
604	A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people	Miss Magdalene Ong	604	ASCEPT - Pharmacoepidemiology
605	Warfarin bleeding risk schemes: A systematic review	Miss Saranya Ramesh	605	ASCEPT - Pharmacoepidemiology
606	A model for predicting high bleeding risk among potential warfarin users	Miss Saranya Ramesh	132	ASCEPT - Pharmacoepidemiology
607	Survival outcomes with lenalidomide for relapsed or refractory multiple myeloma at five large Queensland public hospitals	Miss Megan Sharkey	607	ASCEPT - Pharmacoepidemiology
608	Factors associated with use of falls risk increasing drugs in older people with cancer	Mr Justin Turner	608	ASCEPT - Pharmacoepidemiology
609	Laxative use and constipation in community-dwelling adults in Australia	Mr Barry Werth	609	ASCEPT - Pharmacoepidemiology
610	Prevalence of cytochrome P450 (CYP) inhibitor-substrate interactions in patients on clopidogrel and omeprazole/esomeprazole and frequency of poor CYP2C19 metabolisers	Mr Mohitosh Biswas	610	ASCEPT - Pharmacogenomics
611	From personalized medicine to personalized justice: The promises of translational pharmacogenomics in the justice system. Pharmacogenetic assessment of three homicides.	Dr Yolande Lucire	611	ASCEPT - Pharmacogenomics
612	NQO1-dependent Mito-Toxicity of Clotrimazole	Ms Jamuna Chhetri	179	ASCEPT - Toxicology
613	The effects of over supplementation of vitamins and minerals on oocyte and embryo quality, and subsequent pregnancy rates in sub-fertile patients undergoing IVF treatment in South Australia	Dr Ian Musgrave	613	ASCEPT - Toxicology
614	Caffeine adulteration in herbal weight loss preparations	Miss Rachael Farrington	614	ASCEPT - Toxicology
615	Integration of multiple computational models of bioassays improve in vivo rodent carcinogenicity prediction	Mr Davy Guan	178	ASCEPT - Toxicology
616	Ageing and drug induced liver injury: Insights from animal studies	Mr John Mach	180	ASCEPT - Toxicology
617	In vitro cytotoxicity induced by Pituri, the Aboriginal Australian smokeless tobacco	Assoc Prof Kathryn Steadman	617	ASCEPT - Toxicology
618	Toxicological analysis of traditional Vietnamese herbal medicines for pharmaceuticals and residual Agent Orange compounds	Dr Ian Musgrave	618	ASCEPT - Toxicology
619	Dofetilide-induced hypoxia during rat embryonic development	Dr Diana Oakes	619	ASCEPT - Toxicology
620	The in vivo and in vitro cardiovascular effects of Russell's Viper Venom	Miss Rahini Ragavan	620	ASCEPT - Toxicology
620.1	Paracetamol hepatotoxicity in mice: Effect of age, frailty, N-acetyl cysteine and exposure type	Ms Alice Kane	222	ASCEPT - Toxicology
621	Depressed effect of aging on contractile response of porcine distal ureter to 5-hydroxytryptamine via 5-HT _{2A} receptor subtype	Prof Russ Chess-Williams	621	ASCEPT - Urogenital and Gastrointestinal
622	The involvement of pannexin-1 channels and purinergic P2X ₇ receptors in cytokine-induced colitis in human colonic mucosa	Miss Erica Diezmos	319	ASCEPT - Urogenital and Gastrointestinal
623	New horizons for male contraception: A non-hormonal approach via blockade of P2X ₁ -purinoceptors and α 1A--adrenoceptors	Ms Nicole Eise	223	ASCEPT - Urogenital and Gastrointestinal
624	Effect of inflammatory cytokines on urothelial cell ATP release in vitro	Assoc Prof Kylie Mansfield	624	ASCEPT - Urogenital and Gastrointestinal
625	Altered relaxant responses to isoprenaline and 5'-N-ethylcarboxamidoadenosine observed in whole bladders from diabetic mice	Assoc Prof Roselyn Rose Meyer	625	ASCEPT - Urogenital and Gastrointestinal
626	Expression and localisation of CALHM1 and Pannexin1 in porcine bladder and their involvement in modulating ATP release	Mr Hafiz Sana-Ur-Rehman	626	ASCEPT - Urogenital and Gastrointestinal
627	Will the circle be unbroken? An electronic model of chronic hepatitis C virus infection and its treatment	Mr Tim Shaw	627	ASCEPT - Urogenital and Gastrointestinal
628	A Sarawak jungle ginger - <i>Costus speciosus</i> inhibits nerve mediated smooth muscle contraction of the isolated rat prostate gland	Miss Eunice Su	628	ASCEPT - Urogenital and Gastrointestinal

Wednesday, 2 December

9:30am - 10:25am

Posterboard number	Presentation title	Presenter	Paper reference	Theme
436	Practice makes perfect: Adherence a possible marker of inhaler technique maintenance	Miss Elizabeth Azzi	436	APSA - Pharmacy Practice
437	An audit of medications across two sites of an aged care organization in South Australia	Dr Elizabeth Hotham	437	APSA - Pharmacy Practice
438	Hospital evaluation of medicine usage.....past its DUE date?	Ms Margaret Jordan	438	APSA - Pharmacy Practice
439	An analysis of prescribing and supply of medicines for ophthalmic surgery in NSW hospitals	Ms Margaret Jordan	439	APSA - Pharmacy Practice
440	Evaluation of the physical, chemical and microbiological stability of compounded minoxidil suspension	Miss Ei Lwin	440	APSA - Pharmacy Practice
441	Evaluation of the physical, chemical and microbiological stability of compounded carbimazole suspension	Miss Ei Lwin	441	APSA - Pharmacy Practice
443	Management of cardiovascular risk in clozapine patients: How can we optimise it?	Dr Jose Manuel Serrano Santos	443	APSA - Pharmacy Practice
444	The role of community pharmacists on the assessment of swallowing difficulties of medications: Consumers' perceptions	Dr Jose Manuel Serrano Santos	444	APSA - Pharmacy Practice
445	Information seeking behaviours of breastfeeding women when considering the use of over-the-counter medicines	Dr Alison Shield	445	APSA - Pharmacy Practice
446	Sustainable me – A pharmacist's role in reducing the carbon footprint of healthcare delivery	Mrs Judith Singleton	446	APSA - Pharmacy Practice
447	Stability evaluation of piperacillin and tazobactam in syringes	Dr Yunmei (May) Song	447	APSA - Pharmacy Practice
448	Antimicrobial prescribing for urinary tract infections in a residential aged care setting	Dr Joy Spark	448	APSA - Pharmacy Practice
449	Effectiveness of implementation strategies for clinical guidelines to community pharmacy: A systematic review	Ms Kim Watkins	449	APSA - Pharmacy Practice
450	A qualitative evaluation of the implementation of guidelines and a support tool for asthma management in primary care	Ms Kim Watkins	450	APSA - Pharmacy Practice